Navigation Links
Seaside publishes research supporting disease-modifying potential of STX209 for fragile X syndrome
Date:9/19/2012

de of effect observed with STX209 is comparable to that reported for selective mGluR5 antagonists. These results demonstrate that STX209 has the potential to modify the underlying disease of patients with FXS and support the development of STX209 in the clinic.

Study authors included Christina Henderson, Aileen M. Healy, Matthew Shumway, Rebecca S. Hammond, Friso R. Postima, Christopher Brynczka, Roger Rush and Randall L. Carpenter of Seaside Therapeutics; Lasani Wijetunge and Peter C. Kind of the University of Edinburgh; Mika Nakamoto Kinoshita and Stephen T. Warren of Emory University; Alicia Thomas and Richard Paylor of Baylor College of Medicine; Peter W. Vanderklish of The Scripps Research Institute; and Mark F. Bear of the Massachusetts Institute of Technology.

The accompanying paper, "Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, Phase 2 trial," detailed the results previously announced from the Company's Phase 2 trial. The randomized, double-blind, placebo-controlled Phase 2 study was designed to evaluate the clinical effects of STX209 in 63 subjects, age 6-40 years, with a full mutation of the FMR1 gene. As previously reported, STX209 was well-tolerated and no metabolic side effects were observed. The most common adverse events in subjects receiving STX209 were upper respiratory infections (13%), sedation (8%) and headache (8%), compared to 10%, 2% and 2%, respectively, while receiving placebo. In per-protocol analyses, improvement was seen on the visual analog scale (VAS) ratings of parent-nominated problem behaviors and positive trends were observed on multiple global measures. While improvement was noted on the Irritability subscale of the Aberrant Behavior Checklist (ABC-I), the study's primary endpoint, the magnitude was comparable to that observed on placebo and did not achieve statistical significance.

Social avoidance is a core symptom
'/>"/>

Contact: Kari Watson
kwatson@macbiocom.com
781-235-3060
MacDougall Biomedical Communications, Inc.
Source:Eurekalert

Page: 1 2 3 4

Related biology technology :

1. Receptos Co-Publishes Highest Resolution G-Protein Coupled Receptor Structure to Date in Science
2. Nonprofit Consortium Publishes Review of Skullcap Adulteration
3. Nucleic Acids Research Journal Publishes Sapphire Energy Peer-Reviewed Research Paper on a Chloroplast Genome From Green Algae
4. American Botanical Council Publishes a History of Adulteration
5. Stanford faculty awarded $2.2 million for innovative energy research
6. Electronics without current: Finnish team to research the future of nanoelectronics
7. Elsevier Offers Entire Collection of Journals and Books to Innovators in Developing Countries Through the Access to Research for Development and Innovation (ARDI) Program
8. Metabolic engineer synthesizes key breast milk ingredient, makes research possible
9. Penn researchers make first all-optical nanowire switch
10. Palatin Technologies Provides Update Regarding Its Obesity Research/Development Collaboration with AstraZeneca
11. All Market Research New Report @ Polyvinyl Chloride (PVC) Global Market to 2020 - Growth from Asia-Pacific Construction, Packaging and Electrical Sectors Continues to Drive Demand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... Sept. 2, 2015 Axovant Sciences Ltd. (NYSE:  AXON), ... dementia, today announced upcoming presentations at three investor conferences: ... Baird 2015 Healthcare Conference in New York ... September 10 at 2:00 PM at the BioCentury NewsMakers Conference ... Broadway Hotel & Conference Center , Thursday, September 17 ...
(Date:9/2/2015)... Sept. 2, 2015 Research and ... addition of Jain PharmaBiotech,s new report ... their offering. An increasing ... biotechnology industries is anticipated. Nanotechnology will be ... - from formulations for optimal delivery to ...
(Date:9/2/2015)... ANN ARBOR, Mich. and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... NSF International, a leading provider of regulatory compliance, quality systems, ... acquired Avarent LLC, a consulting firm with expertise in medical device products/processes ...
(Date:9/2/2015)... 02, 2015 Research ... addition of Jain PharmaBiotech,s new report "DNA ... their offering. This report briefly reviews ... technologies, and their applications. Current large and small ... them. Various applications of sequencing are described including ...
Breaking Biology Technology:Axovant Sciences To Present At Upcoming Investor Conferences 2Axovant Sciences To Present At Upcoming Investor Conferences 3Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 2Global Nanobiotechnology Applications, Markets and Companies Report 2015-2024 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2
... Launch of First Three Diagnostic Tests Based on Company,s microRNA ... Technology on Schedule for ... Rosetta Genomics, Ltd. (NASDAQ: ROSG ), a leading,molecular diagnostics company, ... quarter of 2007 compared with corresponding,period of 2006, and said it ...
... presented at national conference provides important insight into ... treatments is jeopardizing quit attempts, PORTLAND, Ore., ... smoking cessation are gathering at the annual meeting ... (SRNT) to present the,latest research on smoking cessation, ...
... Continued year over year growth driven by Loestrin 24 ... Warner Chilcott,Limited (Nasdaq: WCRX ) today announced ... 2007. Revenue in the quarter ended December 31, 2007,totaled ... year quarter.,Revenue for the year ended December 31, 2007 ...
Cached Biology Technology:Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 2Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 3Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 4Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 5Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 6Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 7Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 8Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 9Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 10Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 11Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results 12Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 2Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 3Misperceptions About Smoking Cessation Aids May Hinder Smokers From Using Effective Treatment for Quitting 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 2Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 3Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 5Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 6Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 7Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 8Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 9Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 10Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 11Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 12Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 13Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 14Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 15Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 16Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 17
(Date:9/2/2015)... Security of data and assets has ... organizations, telecommunications, hospitals, as well as individuals. Keys, ... used to prevent unauthorised access. Technological advancements resulted ... could gain access to secure premises after being ... devices and numeric codes. However, hackers also could ...
(Date:9/2/2015)... , September 2, 2015 ... security purpose implied in a system which uses ... voice, signature, iris, vein, DNA and finger print. ... forced to develop such system which provides high ... password, PIN, Patterns and tokens are vulnerable to ...
(Date:9/1/2015)... , Sept. 1, 2015  Automation and ... during airport passenger screening. This is the first ... screening process will become unintrusive. An assortment of ... on voluntary background investigations will transform the passenger ... & Sullivan, Global Airport Passenger Screening Market ...
Breaking Biology News(10 mins):Global Biometrics Spending Market in the Government Sector 2015-2019 2Global Biometrics Spending Market in the Government Sector 2015-2019 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 2Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 3Biometrics Technology Market is Expected to Reach $13.8 Billion by 2015: Hexa Research Inc. 4The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 2The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 3The Future of Airport Security: Passenger Screening Transitioning Into an Invisible Process 4
... expand the options for controlling schizophrenia by identifying a ... of antipsychotic drug. The findings illustrate for the first ... target for developing future antipsychotic drugseven those that have ... published during the week of Nov. 3 in the ...
... The National Science Foundation (NSF) is funding a ... 24 high-achieving science and math undergraduates for teaching careers. ... Program within the College of Arts and Sciences at ... mathematics majors to become high school math and science ...
... virus strain called H5N1 forms tiny tubules in which it ... which otherwise would prompt an antiviral immune response from infected ... report in the journal Nature . Two domains ... tubules where double-stranded RNA is hidden from the immune system, ...
Cached Biology News:Pitt research identifies new target in brain for treating schizophrenia 2NSF grant to launch undergrads from Case Western Reserve into math and science teaching 2NSF grant to launch undergrads from Case Western Reserve into math and science teaching 3Protein 'tubules' free avian flu virus from immune recognition 2
... DeCypher combines enterprise-scale sequence analysis software with ... bioinformatics analyses. With DeCypher, you can perform searches ... ESTs vs NCBI NT database in under 6 ... to genomic DNA Use HMM analysis ...
...
Mouse polyclonal antibody to ALS2CR8 - amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 8...
...
Biology Products: